European Commission approves Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvantTecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the firstand only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeToday ’s approval marksTecentriq ’s sixth lung cancer indication in EuropeBasel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adults with non-small cell lung cancer (NSCLC) with a high risk of recurrence* whose tumours express PD-L1≥50% and who do not have EGFR mutant or ALK-positive NSCLC.“Today’s approval represents an important advance, as Tecentriq becomes the first cancer immunotherapy approved in Europe for the treatment of certain types of early-stage NSCLC,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Since approximately half of all people with early NSCLC develop recurrence after surgery, which in some cases is no longer curable, treating this cancer at an earlier stage offers the best chance to prevent recurrence.”This approval is based on results from an interim analysis of the Phase III IMpower010 study. The results showed treatment with Tecentriq, following complete resection and platinum-based chem...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Breast Cancer | Breast Carcinoma | Canada Health | Cancer | Cancer & Oncology | Carcinoma | Cardiovascular & Thoracic Surgery | Chemotherapy | China Health | Gastroenterology | Genetics | Head and Neck Cancer | Hepatocellular Carcinoma | Immunotherapy | International Medicine & Public Health | Internet | Japan Health | Learning | Liver Cancer | Lung Cancer | Melanoma | Men | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | OBGYN | Partnerships | Pharmaceuticals | Politics | Science | Skin | Skin Cancer | Small Cell Lung Cancer | Spain Health | Study | Switzerland Health | Universities & Medical Training | USA Health | WHO